Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review
As of August 16, 2021, there have been 207,173,086 confirmed cases and 4,361,996 deaths due to the coronavirus disease (COVID-19), and the pandemic remains a global challenge. To date, no effective and approved drugs are available for the treatment of COVID-19. Angiotensin-converting enzyme 2 (ACE2)...
Main Authors: | Bhagat Singh, Dheer Singh, Vinod Verma, Ramakant Yadav, Raj Kumar |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-04-01
|
Series: | Journal of Pharmaceutical Analysis |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095177921001465 |
Similar Items
-
Renin-angiotensin and kallikrein-kinin systems in diabetic retinopathy
by: Igić Rajko
Published: (2019-01-01) -
Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
by: Michael Pan, et al.
Published: (2021-12-01) -
The Renin–Angiotensin System in COVID-19: Can Long COVID Be Predicted?
by: Simone König, et al.
Published: (2023-06-01) -
Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
by: Elena Raccuglia, et al.
Published: (2009-11-01) -
Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)